PubRank

Bartolome Celli

Author PubWeight™ 124.90‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007 19.86
2 A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008 17.19
3 Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012 7.67
4 Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011 5.69
5 American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006 5.65
6 Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009 5.51
7 Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010 5.17
8 Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med 2015 4.16
9 Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med 2012 3.44
10 Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012 2.52
11 Gene expression profiling of human lung tissue from smokers with severe emphysema. Am J Respir Cell Mol Biol 2004 2.33
12 Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009 2.31
13 Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 2009 2.20
14 A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet 2011 1.98
15 Biologic lung volume reduction in advanced upper lobe emphysema: phase 2 results. Am J Respir Crit Care Med 2009 1.78
16 Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012 1.72
17 Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 2007 1.61
18 Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD 2004 1.46
19 Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013 1.41
20 Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis 2012 1.38
21 Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006 1.30
22 Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc 2011 1.28
23 Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010 1.25
24 Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD. Chest 2002 1.23
25 Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med 2014 1.20
26 Biological lung volume reduction: a new bronchoscopic therapy for advanced emphysema. Chest 2007 1.15
27 Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med 2010 1.13
28 Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. Respir Med 2010 1.11
29 Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. Respir Med 2011 1.11
30 Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. Respirology 2011 1.09
31 The COPD Biomarker Qualification Consortium (CBQC). COPD 2013 1.06
32 Cardiopulmonary exercise testing: relevant but underused. Postgrad Med 2010 0.97
33 Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res 2011 0.96
34 Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. Thorax 2011 0.95
35 Changes in body composition in patients with chronic obstructive pulmonary disease: do they influence patient-related outcomes? Ann Nutr Metab 2013 0.91
36 Use of proteomic patterns of serum biomarkers in patients with chronic obstructive pulmonary disease: correlation with clinical parameters. Proc Am Thorac Soc 2006 0.88
37 Adverse health consequences in COPD patients with rapid decline in FEV1--evidence from the UPLIFT trial. Respir Res 2011 0.87
38 Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. Respir Med 2013 0.87
39 Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trial. Lung 2011 0.87
40 Characterizing functional lung heterogeneity in COPD using reference equations for CT scan-measured lobar volumes. Chest 2013 0.86
41 COPD, inflammation and its modulation by phosphodiesterase 4 inhibitors: time to look beyond the FEV1. Chest 2006 0.82
42 Resting handgrip force and impaired cardiac function at rest and during exercise in COPD patients. Respir Med 2011 0.81
43 Improving the care of COPD patients - suggested action points by the COPD exacerbations taskforce for reducing the burden of exacerbations of COPD. Prim Care Respir J 2006 0.80
44 Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD. Respir Res 2014 0.80
45 A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in Chronic Obstructive Pulmonary Disease. BMC Syst Biol 2014 0.80
46 Lung-Function Trajectories and Chronic Obstructive Pulmonary Disease. N Engl J Med 2015 0.79
47 Premature discontinuation during the UPLIFT study. Respir Med 2011 0.79
48 Obstructive lung disease in Mexican Americans and non-Hispanic whites: an analysis of diagnosis and survival in the National Health and Nutritional Examination Survey III Follow-up Study. Chest 2014 0.79
49 Common genetic variants associated with resting oxygenation in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2014 0.78
50 Longitudinal Changes in Handgrip Strength, Hyperinflation, and 6-Minute Walk Distance in Patients With COPD and a Control Group. Chest 2015 0.78
51 Electromyographic validation of the mouth pressure-time index: a noninvasive assessment of inspiratory muscle load. Respir Med 2003 0.78
52 Venous admixture in COPD: pathophysiology and therapeutic approaches. COPD 2008 0.77
53 Reply: minimal or maximal clinically important difference: using death to define MCID. Am J Respir Crit Care Med 2013 0.77
54 Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials. Int J Chron Obstruct Pulmon Dis 2011 0.76
55 Functional capacity, health status, and inflammatory biomarker profile in a cohort of patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil Prev 2015 0.76
56 Chronic obstructive pulmonary disease: different risk factors and different natural histories? Am J Respir Crit Care Med 2014 0.75
57 Long-Term Noninvasive Ventilation in Chronic Stable Hypercapnic Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020 0.75
58 Tracheobronchitis caused by methicillin-resistant Staphylococcus aureus as a cause of chronic wheezing in a non-ventilated adult patient with tracheobronchomalacia. Respiration 2009 0.75
59 Physiologic responses to long-term ventilation. Respir Care Clin N Am 2002 0.75